<DOC>
	<DOCNO>NCT02600598</DOCNO>
	<brief_summary>This Phase I , single-centre , open label , within-subject comparison trial explore biological effect LEO 43204 Gel , 0.037 % , apply daily 3 consecutive day patient actinic keratosis upper extremity . The treatment area patient define contiguous area 250 cm2 skin upper extremity ( include dorsum manus ) contain minimum 5 AK lesion . Additionally must least one AK lesion locate non-treated area contralateral arm . All eligible subject receive LEO 43204 Gel , 0.037 % , treatment area Days 1 , 2 3 . Study medication application ( sub ) investigator apply . A total 30 patient enrol study ( n=15 two group ) . Patients divide two group different biopsy schedule .</brief_summary>
	<brief_title>Biological Effects LEO 43204 Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Signed date informed consent obtain . 2 . Subjects least 5 nonkeratotic , clinically typical , visible discrete AK lesion within contiguous 250 cm2 area ( AK Treatment Area ) upper extremity , 3 . Subjects one additional AK lesion locate contralateral arm . 4 . Subjects area normal skin close proximity AK Treatment Area contralateral arm . 5 . Male female subject , 18 year old . 6 . Agreement patient allow photograph select treatment area take used part study data package 7 . Ability follow study instruction likely complete study requirement 8 . Female Subjects must either nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus tubal litigation ) , childbearing potential* provide confirmed negative pregnancy test prior trial treatment rule pregnancy . Female subject consider childbearing potential unless hysterectomy undergone tubal litigation postmenopausal least one year prior first visit . 9 . Female subject childbearing potential must willing use effective contraception trial entry completion . Effective contraception define follow : Abstinence ( line prefer usual life style subject ) . Vasectomised partner ( give subject monogamous ) . An intrauterine device . Double barrier method define two distinct method ( two actual barrier method ) . Hormonal contraceptive ( oral hormonal birth control , oestrogenic vaginal ring , percutaneous contraceptive patch , implant injectables ) least one menstrual cycle prior enrolment . 1 . Prior treatment ingenol mebutate gel treatment area within last 12 month . 2 . Previously assign treatment clinical trial previously participate clinical trial LEO 43204 programme ( presently LP008468 , LP00841013 , LP00841014 , LP00841015 , LP00841148 , LP00841077 , LP00841193 , LP00841194 , LP00841195 , LP00841196 ) . 3 . Location select treatment area within 5 cm incompletely heal wound infected area skin ( excl . study related biopsy ) within 5 cm suspect basal cell carcinoma ( BCC ) SCC . 4 . History evidence skin condition study indication would interfere histologically biomarker evaluation study medication ( e.g . eczema , unstable psoriasis , xeroderma pigmentosum ) . 5 . Treatment area lesion atypical clinical appearance ( e.g . hypertrophic , hyperkeratotic , recalcitrant disease [ cryosurgery two previous occasion ] and/or cutaneous horn ) . 6 . Known sensitivity allergy ingredient LEO 43204 Gel ( e.g . citric acid ) 7 . Clinical diagnosis/history evidence medical condition would expose subject undue risk significant AE interfere assessment safety course study , determine Investigator clinical judgment . 8 . Anticipated need inpatient hospitalisation inpatient surgery study period . Note cosmetic/therapeutic procedure exclude fall outside criterion detail Prohibited Therapies Medications ( list ) . 9 . Anticipated excessive prolonged exposure ultraviolet light ( e.g . sunlight ) use tan bed duration study 10 . Current participation interventional clinical trial 11 . Subjects receive treatment nonmarketed drug product ( i.e . agent yet make available clinical use follow registration ) within last two month . 12 . Subjects know infected Human Immunodeficiency Virus ( HIV ) . 13 . Subject know , opinion investigator , unlikely comply Clinical Study Protocol ( e.g . alcoholism , drug dependency psychotic state ) . 14 . Females pregnant , childbearing potential wishing become pregnant trial , breast feeding . 15 . Females childbearing potential positive pregnancy test [ screen visit 1 ] . 16 . Previous enrolment clinical trial . Prohibited Therapies and/or Medications : within 2 week prior Screening visit 17 . Cosmetic therapeutic procedure ( e.g . use liquid nitrogen , surgical excision , curettage , dermabrasion , medium great depth chemical peel , laser resurface ) : within 2 cm select treatment area within 2 cm select AK lesion outside treatment area 18 . Use acidcontaining therapeutic product ( e.g . salicylic acid fruit acid , alpha beta hydroxy acid glycolic acid ) , topical retinoids light chemical peel : within 2 cm select treatment area within 2 cm select AK lesion outside treatment area 19 . Use topical salve ( nonmedicated/nonirritant lotion/cream acceptable ) topical steroid : within 2 cm select treatment area within 2 cm select AK lesion outside treatment area ; artificial tanner : within 5 cm select treatment area within 5 cm select AK lesion outside treatment area Prohibited Therapies and/or Medications : within 4 week prior Screening visit 20 . Treatment immunomodulators ( e.g . azathioprine ) , cytotoxic drug ( e.g . cyclophosphamide , vinblastine , chlorambucil , methotrexate , podophyllin , camptothecin ) interferon/interferon inducer . 21 . Treatment systemic medication suppress immune system ( e.g . cyclosporine , prednisone , methotrexate , infliximab ) . 22 . Treatment/therapy UVB Prohibited Therapies and/or Medications : within 8 week prior Screening visit 23 . Treatment 5FU , imiquimod , diclofenac , photodynamic therapy : within 2 cm select treatment area within 2 cm select AK lesion outside treatment area Prohibited Therapies and/or Medications : within 6 month prior Screening visit 24 . Use systemic retinoids ( e.g . isotretinoin , acitretin , bexarotene )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>